The 2020 revision of the guidelines for the management of myeloproliferative neoplasms

Sung Yong Kim, Sung Hwa Bae, Soo Mee Bang, Ki Seong Eom, Junshik Hong, Seongsoo Jang, Chul Won Jung, Hee Jin Kim, Ho Young Kim, Min Kyoung Kim, Soo Jeong Kim, Yeung Chul Mun, Seung Hyun Nam, Jinny Park, Jong Ho Won, Chul Won Choi

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional somatic mutations have a clinical impact on the prognosis of patients harboring these genetic abnormalities. Treatment strategies have also advanced with the introduction of JAK inhibitors, one of which has been approved for the treatment of patients with myelofibrosis and those with hydroxyurea-resistant or intolerant polycythemia vera. Recently developed drugs aim to elicit hematologic responses, as well as symptomatic and molecular responses, and the response criteria were refined accordingly. Based on these changes, we have revised the guidelines and present the diagnosis, treatment, and risk stratification of MPNs encountered in Korea.

Original languageEnglish
Pages (from-to)45-62
Number of pages18
JournalKorean Journal of Internal Medicine
Issue number1
StatePublished - Jan 2021

Bibliographical note

Publisher Copyright:
© 2021 The Korean Association of Internal Medicine.


  • Polycythemia vera
  • Practice guideline
  • Primary myelofibrosis
  • Thrombocythemia, essential


Dive into the research topics of 'The 2020 revision of the guidelines for the management of myeloproliferative neoplasms'. Together they form a unique fingerprint.

Cite this